2024-03-28T09:22:51Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00016913
2023-01-16T04:37:28Z
499:960:1165
Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer
Sahin, TT
Kasuya, H
Nomura, N
Shikano, T
Yamamura, K
Gewen, T
Kanzaki, A
Fujii, T
Sugae, T
Imai, T
Nomoto, S
Takeda, S
Sugimoto, H
Kikumori, T
Kodera, Y
Nishiyama, Y
Nakao, A
open access
angiogenesis
apoptosis
breast cancer
herpes virus
HF10
oncolytic virus
microenvironment
Oncolytic viruses are a promising method of cancer therapy, even for advanced malignancies. HF10, a spontaneously mutated herpes simplex type 1, is a potent oncolytic agent. The interaction of oncolytic herpes viruses with the tumor microenvironment has not been well characterized. We injected HF10 into tumors of patients with recurrent breast carcinoma, and sought to determine its effects on the tumor microenvironment. Six patients with recurrent breast cancer were recruited to the study. Tumors were divided into two groups: saline-injected (control) and HF10-injected (treatment). We investigated several parameters including neovascularization (CD31) and tumor lymphocyte infiltration (CD8, CD4), determined by immunohistochemistry, and apoptosis, determined by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Median apoptotic cell count was lower in the treatment group (P=0.016). Angiogenesis was significantly higher in treatment group (P=0.032). Count of CD8-positive lymphocytes infiltrating the tumors was higher in the treatment group (P=0.008). We were unable to determine CD4-positive lymphocyte infiltration. An effective oncolytic viral agent must replicate efficiently in tumor cells, leading to higher viral counts, in order to aid viral penetration. HF10 seems to meet this criterion; furthermore, it induces potent antitumor immunity. The increase in angiogenesis may be due to either viral replication or the inflammatory response.
名古屋大学博士学位論文 学位の種類 : 博士(医学)(課程) 学位授与年月日:平成25年1月31日 Tevfik Tolga SAHIN氏の博士論文として提出された
nature
2012-04
eng
doctoral thesis
http://hdl.handle.net/2237/18933
https://nagoya.repo.nii.ac.jp/records/16913
https://doi.org/10.1038/cgt.2011.80
0929-1903
Cancer Gene Therapy
19
4
229
237
甲第9929号
博士(医学)
2012-04-01
13901
名古屋大学
Nagoya University
https://nagoya.repo.nii.ac.jp/record/16913/files/k9929_thesis.pdf
application/pdf
214.7 kB
2018-02-20